XPW1

CAS No. 2700286-66-2

XPW1( —— )

Catalog No. M37124 CAS No. 2700286-66-2

XPW1 is a new potent and selective CDK9 inhibitor with antitumour activity that transcriptionally inhibits the DNA repair process in ccRCC cells.XPW1 can be used to study clear cell renal cell carcinoma.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 160 Get Quote
5MG 246 Get Quote
10MG 395 Get Quote
25MG 766 Get Quote
50MG 1030 Get Quote
100MG 1341 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    XPW1
  • Note
    Research use only, not for human use.
  • Brief Description
    XPW1 is a new potent and selective CDK9 inhibitor with antitumour activity that transcriptionally inhibits the DNA repair process in ccRCC cells.XPW1 can be used to study clear cell renal cell carcinoma.
  • Description
    XPW1 is a potent and selective CDK9 inhibitor with excellent activity against clear cell renal cell carcinoma (ccRCC) and low toxicity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2700286-66-2
  • Formula Weight
    656.19
  • Molecular Formula
    C36H39ClFN7O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 31.25 mg/mL (47.62 mM; Ultrasonic (<60°C)
  • SMILES
    ClC1=C(C=2N=C(NCC3=CC(F)=CC=C3)C=CC2)C=C(N[C@H]4CC[C@H](NC(=O)C5=CC=C(NC(/C=C/CN(C)C)=O)C=C5)CC4)N=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kuang Z, et al. The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma. Br J Cancer. 2023 Oct 26.?
molnova catalog
related products
  • AT-7519 hydrochlorid...

    A potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM).

  • Flavopiridol hydroch...

    A potent, ATP-competetive CDKs inhibitor with IC50 of 30, 170, 100 nM for CDk1, 2, 4, respectively.

  • TG003 B

    TG003 is a potent Clk1/Sty inhibitor that inhibits Clk1 and Clk4, inhibits cancer cell growth and induces apoptosis, and can be used in the study of Duchenne muscular dystrophy.